Allspring Global Investments Holdings LLC Boosts Position in Bruker Corporation $BRKR

Allspring Global Investments Holdings LLC boosted its holdings in Bruker Corporation (NASDAQ:BRKR) by 38.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 255,441 shares of the medical research company’s stock after purchasing an additional 70,541 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.17% of Bruker worth $12,289,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Legacy Wealth Asset Management LLC purchased a new stake in Bruker in the fourth quarter valued at $261,000. SG Americas Securities LLC boosted its position in shares of Bruker by 134.5% in the 4th quarter. SG Americas Securities LLC now owns 99,173 shares of the medical research company’s stock valued at $4,672,000 after purchasing an additional 56,880 shares during the period. Diversified Trust Co. acquired a new stake in shares of Bruker in the 4th quarter valued at about $787,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Bruker during the 4th quarter worth $254,000. Finally, Park Avenue Securities LLC grew its position in Bruker by 18.3% during the 4th quarter. Park Avenue Securities LLC now owns 8,670 shares of the medical research company’s stock worth $408,000 after purchasing an additional 1,339 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, VP Mark Munch sold 7,000 shares of Bruker stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00. Following the completion of the transaction, the vice president directly owned 128,443 shares in the company, valued at $7,064,365. The trade was a 5.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 11,000 shares of company stock worth $554,280. Insiders own 27.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on BRKR shares. Guggenheim lowered their price objective on shares of Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Wells Fargo & Company boosted their price target on shares of Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Wolfe Research upgraded shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a research report on Wednesday, December 10th. JPMorgan Chase & Co. lifted their price objective on Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Barclays dropped their target price on Bruker from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $49.77.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $36.76 on Monday. The firm has a market capitalization of $5.60 billion, a price-to-earnings ratio of -245.07, a price-to-earnings-growth ratio of 2.20 and a beta of 1.20. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87. The business’s 50 day simple moving average is $38.60 and its 200-day simple moving average is $41.43. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $56.22.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.06). The firm had revenue of $977.20 million during the quarter, compared to analysts’ expectations of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The business’s revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the business earned $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, March 23rd. Bruker’s dividend payout ratio (DPR) is -133.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.